These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 1852896)

  • 41. [Effect of intra-arterial and intravenous PGE1 infusions on transcutaneous oxygen pressure in patients with critical ischemia of the extremities].
    Weiss T; Griesshaber J; Rogatti W; Kistner O; Hsu E; Jansen T; Diehm C
    Vasa Suppl; 1991; 33():341-2. PubMed ID: 1788749
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vivo disposition of prostaglandin E1 via pharmacokinetic characterization of its pulmonary metabolite.
    Verburg M; Bothwell W; Daniels EG; Fitzpatrick FA
    J Cardiovasc Pharmacol; 1982; 4(6):980-5. PubMed ID: 6185792
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and tolerability of intra-arterial and intravenous prostaglandin E1 infusions in occlusive arterial disease stage III/IV.
    Balzer K; Rogatti W; Rüttgerodt K
    Vasa Suppl; 1989; 28():31-8. PubMed ID: 2609242
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interindividual variation in the enzymatic 15-keto-reduction of 13,14-dihydro-15-keto-prostaglandin E1 in human liver and in human erythrocytes.
    Rady-Pentek P; Mueller R; Tang BK; Kalow W
    Eur J Clin Pharmacol; 1997; 52(2):147-53. PubMed ID: 9174685
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Meta-analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlusive disease stages III and IV.
    Creutzig A; Lehmacher W; Elze M
    Vasa; 2004 Aug; 33(3):137-44. PubMed ID: 15461065
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A comparison of the effect of Lipo PGE1 and other related compounds on experimental peripheral arterial occlusive disease in rats.
    Goto J; Araki H; Otomo S; Aihara H
    Drugs Exp Clin Res; 1986; 12(11):917-21. PubMed ID: 3816509
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prostaglandin E1 increases the blood flow rate of saphenous vein grafts in patients undergoing off-pump coronary artery bypass grafting.
    Zhao L; Lu J; Wang C; Zhao W; Qing E; Ma J
    J Cardiothorac Vasc Anesth; 2013 Dec; 27(6):1208-11. PubMed ID: 24090805
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Haemodynamic effects of intra-arterial and intravenous administration of prostaglandin E1 in patients with peripheral arterial disease.
    Hirai M; Nakayama R
    Br J Surg; 1986 Jan; 73(1):20-3. PubMed ID: 3947867
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The induction of cyclooxygenase-2 elicited by endotoxin in endothelial cells and macrophages is inhibited by prostaglandin E1 and 13,14-dihydro prostaglandin E1.
    Akarasereenont P; Hide E; Ney P; Thiemermann C; Vane JR
    Agents Actions Suppl; 1995; 45():59-64. PubMed ID: 7717202
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The pharmacology of 13,14-dihydro-PGE1 in comparison with PGE1].
    Braun M; Ney P; Hohlfeld T; Szymanski C; Bruch L; Schrör K
    Vasa Suppl; 1991; 33():337-8. PubMed ID: 1788747
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Utilizing immunoaffinity chromatography (IAC) cross-reactivity in GC-MS/MS exemplified at the measurement of prostaglandin E1 in human plasma using prostaglandin E2-specific IAC columns.
    Tsikas D; Suchy MT; Tödter K; Heeren J; Scheja L
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 May; 1021():101-107. PubMed ID: 25944643
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 13,14-Dihydro-prostaglandin E1 decreases low-density lipoprotein influx into rabbit aorta.
    Sinzinger H; Virgolini I; Keiler A; Lupattelli G; Gerakakis A; Peskar BA
    Eur J Pharmacol; 1992 Aug; 219(1):129-33. PubMed ID: 1397039
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vasodilator actions of prostaglandin 6-keto-E1 in the pulmonary vascular bed.
    Hyman AL; Kadowitz PJ
    J Pharmacol Exp Ther; 1980 Jun; 213(3):468-72. PubMed ID: 7193724
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protective action of 6-keto-prostaglandin E1 in traumatic shock.
    Araki H; Lefer AM
    Prostaglandins Med; 1979 Apr; 2(4):277-84. PubMed ID: 575862
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects and arterial concentration of prostaglandin E1 during cardiopulmonary bypass.
    Okuda M; Faruhashi K; Konishi K; Muneyuki M
    Eur J Anaesthesiol; 1991 Mar; 8(2):129-34. PubMed ID: 1874208
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics of vasoactive substances administered into the human corpus cavernosum.
    van Ahlen H; Peskar BA; Sticht G; Hertfelder HJ
    J Urol; 1994 May; 151(5):1227-30. PubMed ID: 8158764
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neutralization of prostaglandin E1 intravenous solution reduces infusion phlebitis.
    Fujita M; Hatori N; Shimizu M; Yoshizu H; Segawa D; Kimura T; Iizuka Y; Tanaka S
    Angiology; 2000 Sep; 51(9):719-23. PubMed ID: 10999612
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Skin surface oxygen pressure fields during administration of prostaglandin E1 in patients with arterial occlusive disease.
    Creutzig A; Caspary L; Alexander K
    Klin Wochenschr; 1990 Feb; 68(4):207-12. PubMed ID: 2314008
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Altered hepatic hemodynamics and improved liver function following intrahepatic vascular infusion of prostaglandin E1.
    Nakai T; Tanimura H; Hirokawa F; Tamaki T
    J Gastroenterol; 1998 Jun; 33(3):362-7. PubMed ID: 9658315
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of adjuvant PGE1 therapy following profundaplasty in patients with severe limb ischaemia. Early and long-term results.
    Gruss JD
    Vasa; 1997 May; 26(2):117-21. PubMed ID: 9174388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.